TMCnet News
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Tokai Pharmaceuticals, Inc. And Advises Investors with Losses to Contact the FirmLundin Law PC (http://lundinlawpc.com/) announces that it is investigating claims against Tokai Pharmaceuticals, Inc. ("Tokai" or the "Company") (Nasdaq: TKAI) concerning possible violations of federal securities laws. To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at [email protected]. No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member. The investigation focuses on whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The investigation is related to a July 26, 2016 announcement that Tokai would end a late-stage trial of its prostate cancer therapy candidate, galeterone, saying that it believed the phase 3 study would not meet its primary endpoint. When this announcement was made public, Tokai shares fell in value. Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160728006743/en/ |
